Literature DB >> 3498565

Interleukin 2 synthesis in the presence of steroids: a model of steroid resistance.

K B Walker1, J M Potter, A K House.   

Abstract

In this study interleukin 2 (IL-2) synthesis by human lymphocytes in the presence and absence of prednisolone in a group of normal subjects has been assessed. An association between suppression in vitro of induced phytohaemagglutinin-blastogenesis by prednisolone and synthesis of IL-2 was found. Those subjects whose lymphocytes are identified as steroid-resistant have significantly higher IL-2 activity in the supernatants of both steroid and non-steroid treated lymphocyte cultures than steroid sensitive subjects. The addition of exogenous IL-2 was found to ablate the suppressive effects of steroids on lymphocyte blastogenesis. These results suggest that significantly greater activity of IL-2 in the culture supernatants of steroid resistant subjects may represent a mechanism for glucocorticoid resistance in vitro and help explain the relationship between increased loss of grafts and steroid resistance in renal allograft recipients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3498565      PMCID: PMC1542675     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  14 in total

1.  Glucocorticoid-induced inhibition of T cell growth factor production. II. The effect on the in vitro generation of cytolytic T cells.

Authors:  S Gillis; G R Crabtree; K A Smith
Journal:  J Immunol       Date:  1979-10       Impact factor: 5.422

2.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

3.  Decreased clearance of prednisolone, a factor in the development of corticosteroid side effects.

Authors:  M Kozower; L Veatch; M M Kaplan
Journal:  J Clin Endocrinol Metab       Date:  1974-03       Impact factor: 5.958

4.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

5.  Glucocorticoid-induced inhibition of T cell growth factor production. I. The effect on mitogen-induced lymphocyte proliferation.

Authors:  S Gillis; G R Crabtree; K A Smith
Journal:  J Immunol       Date:  1979-10       Impact factor: 5.422

6.  Continued growth of functional human T lymphocytes: production of human T-cell growth factor.

Authors:  G D Bonnard; K Yasaka; R D Maca
Journal:  Cell Immunol       Date:  1980-05       Impact factor: 4.868

7.  Cyclosporin A and dexamethasone suppress T cell responses by selectively acting at distinct sites of the triggering process.

Authors:  E L Larsson
Journal:  J Immunol       Date:  1980-06       Impact factor: 5.422

8.  Correlation between ADCC resistance to in vitro steroid and renal allograft failure.

Authors:  L J Dumble; I M Macdonald; P Kincaid-Smith; G J Clunie
Journal:  Transplant Proc       Date:  1981-09       Impact factor: 1.066

9.  Hydrocortisone abrogates proliferation of T cells in autologous mixed lymphocyte reaction by rendering the interleukin-2 Producer T cells unresponsive to interleukin-1 and unable to synthesize the T-cell growth factor.

Authors:  R Palacios; I Sugawara
Journal:  Scand J Immunol       Date:  1982-01       Impact factor: 3.487

10.  Glucocorticoid-binding proteins in human acute lymphoblastic leukemic blast cells.

Authors:  M E Lippman; R H Halterman; B G Leventhal; S Perry; E B Thompson
Journal:  J Clin Invest       Date:  1973-07       Impact factor: 14.808

View more
  10 in total

Review 1.  The melatonin-cytokine connection in rheumatoid arthritis.

Authors:  M Cutolo; G J M Maestroni
Journal:  Ann Rheum Dis       Date:  2005-08       Impact factor: 19.103

2.  In vivo and in vitro effects of glucocorticoids on lectin-induced blastogenesis in atopic dermatitis.

Authors:  M Rupprecht; R Rupprecht; N Wodarz; H U Braner; J Kornhuber; H U Koch; P Riederer; O P Hornstein
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

3.  Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes.

Authors:  S D Hearing; M Norman; C S Probert; N Haslam; C M Dayan
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

4.  IL-2 and IL-4 counteract budesonide inhibition of GM-CSF and IL-10, but not of IL-8, IL-12 or TNF-alpha production by human mononuclear blood cells.

Authors:  S Larsson; C G Löfdahl; M Linden
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

5.  Soluble interleukin 2 receptor in atopic eczema.

Authors:  G B Colver; J A Symons; G W Duff
Journal:  BMJ       Date:  1989-05-27

Review 6.  Treatment of inflammatory bowel disease: a review of medical therapy.

Authors:  Patricia L Kozuch; Stephen B Hanauer
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

7.  Altered in vitro lymphocyte response in childhood nephrotic syndrome.

Authors:  I K Hewitt; A K House; J M Potter; B F Kinnear
Journal:  Pediatr Nephrol       Date:  1992-09       Impact factor: 3.714

8.  Remission of refractory minimal change nephrotic syndrome after basiliximab therapy.

Authors:  Sung-Shin Park; Won-Ho Hahn; Sung-Do Kim; Byoung-Soo Cho
Journal:  Pediatr Nephrol       Date:  2009-02-26       Impact factor: 3.714

9.  Expression of glucocorticoid receptors in mononuclear cells in nephrotic syndrome.

Authors:  Anna Wasilewska; Walentyna Zoch-Zwierz; Barbara Tomaszewska; Ryszard Wierciński; Anna Stasiak-Barmuta
Journal:  Pediatr Nephrol       Date:  2003-06-12       Impact factor: 3.714

10.  Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma.

Authors:  I M Adcock; S J Lane; C R Brown; T H Lee; P J Barnes
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.